Pipeline
Portfolio of Next Gen GPCR-targeted therapeutics for obesity and metabolic disorders
Orion’s novel technology has enabled us to produce a diversified portfolio of next generation metabolic targets, with differentiated profiles to address unmet needs.
Drug / Target
indication
Phase
Oncology
IND Enabling
OB-002 / CCR5
Infections Disease
Ph1 Trial Complete
COVID-19 ARDS
PoC Complete
Neuroinflam
PoC Complete
OB-003 / CCR9
Oncology
Lead Optimization
IBD
Lead Optimization
OB-004 / CCR2
Oncology
PoC
Inflammation
PoC
Undisclosed
Oncology
Target Validation
Metabolic
Target Validation
Undisclosed Orphan
Oncology
Lead Discovery
Oncology2
Target Validation
DRUG / TARGET
DISCOVERY
PoC
IND Enabling
Clinical Trials
Phase 1 Phase 2/3
OB-002 / CCR5
oncology
Infectious Disease
COVID-19 ARDS
Neuroinflammation
OB-003 / CCR9
Oncology
IBD
OB-004 / CCR2
Oncology
Inflammation
Undisclosed
Oncology
Metabolic
Undisclosed Orphan
Oncology 1
Oncology 2
Global Headquarters
343 Preston Street
11th floor,
Ottawa, On K1S 1N4
CANADA
+1 343.291.1032
Switzerland
Campus Biotech
Innovation Park
Avenue de Sécheron 15
1202 Genève
SWITZERLAND
Poland
Orion Biotechnology
Life Science Park
UI Bobrzyńskiego 14
30-348 Krakôw
POLAND
